Literature DB >> 15825084

Hepatitis C virus expression suppresses interferon signaling by degrading STAT1.

Wenyu Lin1, Won Hyeok Choe, Yoichi Hiasa, Yoshitaka Kamegaya, Jason T Blackard, Emmett V Schmidt, Raymond T Chung.   

Abstract

BACKGROUND & AIMS: The molecular mechanisms by which hepatitis C virus (HCV) antagonizes the antiviral actions of interferon (IFN) have not been fully characterized. Specifically, how HCV proteins impact on IFN signaling components has yet to be elucidated. We used an HCV cell-based expression model to examine the interaction between HCV protein expression and host type I IFN signaling components in the Jak-STAT kinase pathway.
METHODS: Full-length HCV and HCV subgenomic constructs corresponding to structural and each of the nonstructural proteins were transiently transfected into Huh-T7 cells. HCV expression was monitored by an HCV core antigen enzyme-linked immunosorbent assay. STAT1, P-STAT1, and HCV protein expression was investigated with immunoprecipitation and Western blots.
RESULTS: Overexpression and small interfering RNA studies showed that STAT1 was indispensable for control of HCV expression. STAT1 and P-STAT1 expression were markedly reduced in HCV-transfected cells. Full-length HCV, HCV core/E1/E2, and NS3-4A were each associated with decreased STAT1 expression, which was attributable to proteasome-dependent degradation of STAT1. HCV core, but not HCV E1, E2, NS3, NS4, or NS5, bound to STAT1. STAT2 expression was not affected by HCV.
CONCLUSIONS: HCV expression selectively degrades STAT1 and reduces P-STAT1 accumulation in the nucleus in a proteasome-dependent manner. HCV core protein binds STAT1, suggesting that this viral protein is associated with STAT1 degradation. STAT1 plays an indispensable role in innate antiviral immunity against HCV expression. In turn, HCV subverts the Jak-STAT kinase by selectively inducing STAT1 degradation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825084     DOI: 10.1053/j.gastro.2005.02.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  73 in total

1.  Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.

Authors:  Wenyu Lin; Wei-Lun Tsai; Run-Xuan Shao; Guoyang Wu; Lee F Peng; Lydia L Barlow; Woo Jin Chung; Leiliang Zhang; Hong Zhao; Jae-Young Jang; Raymond T Chung
Journal:  Gastroenterology       Date:  2010-03-12       Impact factor: 22.682

2.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

3.  EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Authors:  Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

7.  Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.

Authors:  Kyung-Ah Kim; Wenyu Lin; Andrew W Tai; Run-Xuan Shao; Ethan Weinberg; Carolina B De Sa Borges; Atul K Bhan; Hui Zheng; Yoshitaka Kamegaya; Raymond T Chung
Journal:  J Hepatol       Date:  2009-02-14       Impact factor: 25.083

Review 8.  Treatment failure in hepatitis C: mechanisms of non-response.

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Hepatol       Date:  2008-12-03       Impact factor: 25.083

9.  The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.

Authors:  Wenyu Lin; Chuanlong Zhu; Jian Hong; Lei Zhao; Nikolaus Jilg; Dahlene N Fusco; Esperance A Schaefer; Cynthia Brisac; Xiao Liu; Lee F Peng; Qikai Xu; Raymond T Chung
Journal:  J Hepatol       Date:  2014-12-03       Impact factor: 25.083

Review 10.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.